Finance

Lists
TKPHF:OTCMKTS
Takeda Pharmaceutical Co Ltd
33,85 $
0,00%
(0,00) 1D
37,50 $
+10,79% (+3,65)
Pre-market
Closed: 6 հոկ, 11:51:40 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TKPHF...
Mkt. cap
58,79 մլրդ
Avg. vol.
2,49 հզր
Volume
400,00
52-wk high
39,20 $
52-wk low
26,33 $
Beta
-2,60
Shares outstanding
1,60 մլրդ
No. of employees
47 հզր
Mkt. cap
58,79 մլրդ
Avg. vol.
2,49 հզր
Volume
400,00
52-wk high
39,20 $
52-wk low
26,33 $
Beta
-2,60
Shares outstanding
1,60 մլրդ
No. of employees
47 հզր
News stories
From web sources and news partners
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47 հզր
Founded12 հնս, 1781 թ.
Headquarters-
Sector-
Websitetakeda.com
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,11 տրլն
1,19 տրլն
1,09 տրլն
1,22 տրլն
Cost of goods sold
380,06 մլրդ
401,15 մլրդ
453,33 մլրդ
406,68 մլրդ
Cost of revenue
380,06 մլրդ
401,15 մլրդ
453,33 մլրդ
406,68 մլրդ
Research and development expenses
161,48 մլրդ
175,23 մլրդ
187,96 մլրդ
167,40 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
253,55 մլրդ
282,78 մլրդ
291,96 մլրդ
286,51 մլրդ
Operating expense
562,57 մլրդ
661,30 մլրդ
519,65 մլրդ
612,60 մլրդ
Total operating expenses
942,63 մլրդ
1,06 տրլն
972,98 մլրդ
1,02 տրլն
Operating income
170,17 մլրդ
129,25 մլրդ
121,56 մլրդ
200,62 մլրդ
Other non operating income
77,96 մլրդ
-197,22 մլրդ
181,53 մլրդ
-28,14 մլրդ
EBT including unusual items
28,17 մլրդ
133,86 մլրդ
-455,02 մլրդ
162,72 մլրդ
EBT excluding unusual items
128,86 մլրդ
114,17 մլրդ
71,49 մլրդ
161,92 մլրդ
Income tax expense
39,90 մլրդ
30,13 մլրդ
-86,62 մլրդ
49,46 մլրդ
Effective tax rate
141,64%
22,51%
19,04%
30,40%
Other operating expenses
16,12 մլրդ
67,13 մլրդ
-64,27 մլրդ
53,17 մլրդ
Net income
-11,80 մլրդ
103,64 մլրդ
-368,47 մլրդ
113,20 մլրդ
Net profit margin
-1,06%
8,70%
-33,66%
9,28%
Earnings per share
-
-
-
-
Interest and investment income
43,92 մլրդ
181,35 մլրդ
-
24,61 մլրդ
Interest expense
-161,10 մլրդ
-
-239,63 մլրդ
-35,70 մլրդ
Net interest expenses
-117,18 մլրդ
181,35 մլրդ
-239,63 մլրդ
-11,09 մլրդ
Depreciation and amortization charges
-
-
-
-
EBITDA
355,15 մլրդ
319,89 մլրդ
192,73 մլրդ
363,66 մլրդ
Gain or loss from assets sale
303,00 մլն
358,00 մլն
1,46 մլրդ
-6,00 մլրդ
AI content may include mistakes. Learn more
Google Apps